Clinical Trials Directory

Trials / Unknown

UnknownNCT04141215

Allogeneic Bone Paste Versus Allogeneic Bone Powder

Allogeneic Bone Paste Versus Allogeneic Bone Powder in Pre-implant Guided Bone Regeneration in Oral Surgery: a Randomized Non-inferiority Clinical Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
86 (estimated)
Sponsor
Biobank · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Autogenous bone graft has been considered the gold standard in Guided Bone Regeneration (GBR) technique used for bone augmentation. However, there are disadvantages associated with autograft use such as limited amount of available bone and increased morbidity for the patient at the sampling site. Several biomaterials have been used as a replacement of the autogenous bone. Viral-inactivated bone allograft powder is an alternative that has proven efficacy and tolerance. This study aims to assess the non-inferiority of viral-inactivated allogeneic bone paste compared to a viral-inactivated cortico-cancellous allogenic bone powder in achieving the ideal bone volume.

Conditions

Interventions

TypeNameDescription
BIOLOGICALBIOBank bone pasteBIOBank bone paste (PPT322)
BIOLOGICALBIOBank cortico-cancellous bone powderBIOBank cortico-cancellous bone powder (PPT6)

Timeline

Start date
2019-11-15
Primary completion
2022-11-30
Completion
2022-11-30
First posted
2019-10-28
Last updated
2022-03-02

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04141215. Inclusion in this directory is not an endorsement.